Dear Colleagues,

Please find below details of a high priority clinical study just opened to patient accrual at Northwestern Medicine Developmental Therapeutics Institute (NMDTI).

**A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA**

Please click on this [Eligibility Criteria](#) link to see more patient-specific information.

If you would like more information on this or any other NMDTI study, please click on any name below to generate a contact email or reply directly to this message.

<table>
<thead>
<tr>
<th>Ellen Dammrich, MSN, FNP-BC</th>
<th>Hannah Garrett, MSN, AGPCNP-BC</th>
<th>Francis J Giles, MD</th>
<th>Adam Petrich, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:edammric@nmh.org">edammric@nmh.org</a></td>
<td><a href="mailto:hgarrett@nmh.org">hgarrett@nmh.org</a></td>
<td><a href="mailto:francis.giles@northwestern.edu">francis.giles@northwestern.edu</a></td>
<td><a href="mailto:apetrich@nmff.org">apetrich@nmff.org</a></td>
</tr>
</tbody>
</table>

**Key Targets in DLBCL**

![Key Targets in DLBCL Diagram](image)
Study Design

3+3 dose escalation trial exploring doublets and triplets containing CC-122, CC-223, CC-292 and rituximab

Patient Population

R/R DLBCL (de novo or transformed)
At least one prior line of therapy (R-CHOP or similar)
High risk pre-ASCT or > 3 months post-ASCT
No prior TORC1/2 or BTK inhibitors (rapalogs, PI3Ki, lenalidomide prior therapy allowed)

Study Schema

For more information about this study, or any other study, please contact NMDTI at nmdti@northwestern.edu or by calling 2-1234. To learn more about NMDTI, please visit www.nmdti.org